Weaver Lynne C, Bao Feng, Dekaban Gregory A, Hryciw Todd, Shultz Sandy R, Cain Donald P, Brown Arthur
Spinal Cord Injury Team, Molecular Medicine, Robarts Research Institute, The University of Western Ontario, London, Ontario N6A 5B7, Canada; Department of Physiology and Pharmacology, The University of Western Ontario, London, Ontario N6A 5B7, Canada.
Spinal Cord Injury Team, Molecular Medicine, Robarts Research Institute, The University of Western Ontario, London, Ontario N6A 5B7, Canada.
Exp Neurol. 2015 Sep;271:409-22. doi: 10.1016/j.expneurol.2015.07.003. Epub 2015 Jul 11.
Traumatic CNS injury triggers a systemic inflammatory response syndrome (SIRS), in which circulating inflammatory cells invade body organs causing local inflammation and tissue damage. We have shown that the SIRS caused by spinal cord injury is greatly reduced by acute intravenous treatment with an antibody against the CD11d subunit of the CD11d/CD18 integrin expressed by neutrophils and monocyte/macrophages, a treatment that reduces their efflux from the circulation. Traumatic brain injury (TBI) is a frequently occurring injury after motor vehicle accidents, sporting and military injuries, and falls. Our studies have shown that the anti-CD11d treatment diminishes brain inflammation and oxidative injury after moderate or mild TBI, improving neurological outcomes. Accordingly, we examined the impact of this treatment on the SIRS triggered by TBI. The anti-CD11d treatment was given at 2h after a single moderate (2.5-3.0 atm) or 2 and 24h after each of three consecutive mild (1.0-1.5 atm) fluid percussion TBIs. Sham-injured, saline-treated rats served as controls. At 24h, 72 h, and 4 or 8 weeks after the single TBI and after the third of three TBIs, lungs of rats were examined histochemically, immunocytochemically and biochemically for downstream effects of SIRS including inflammation, tissue damage and expression of oxidative enzymes. Lung sections revealed that both the single moderate and repeated mild TBI caused alveolar disruption, thickening of inter-alveolar tissue, hemorrhage into the parenchyma and increased density of intra-and peri-alveolar macrophages. The anti-CD11d treatment decreased the intrapulmonary influx of neutrophils and the density of activated macrophages and the activity of myeloperoxidase after these TBIs. Moreover, Western blotting studies showed that the treatment decreased lung protein levels of oxidative enzymes gp91(phox), inducible nitric oxide synthase and cyclooxygenase-2, as well as the apoptotic pathway enzyme caspase-3 and levels of 4-hydroxynonenal-bound proteins (an indicator of lipid peroxidation). Decreased expression of the cytoprotective transcription factor Nrf2 reflected decreased lung oxidative stress. Anti-CD11d treatment also diminished the lung concentration of free radicals and tissue aldehydes. In conclusion, the substantial lung component of the SIRS after single or repeated TBIs is significantly decreased by a simple, minimally invasive and short-lasting anti-inflammatory treatment.
创伤性中枢神经系统损伤会引发全身炎症反应综合征(SIRS),在该综合征中,循环中的炎性细胞侵入身体器官,导致局部炎症和组织损伤。我们已经表明,通过急性静脉注射一种针对由中性粒细胞和单核细胞/巨噬细胞表达的CD11d/CD18整合素的CD11d亚基的抗体进行治疗,可大大减轻脊髓损伤引起的SIRS,这种治疗可减少炎性细胞从循环中的流出。创伤性脑损伤(TBI)是机动车事故、运动和军事损伤以及跌倒后经常发生的损伤。我们的研究表明,抗CD11d治疗可减轻中度或轻度TBI后的脑部炎症和氧化损伤,改善神经学预后。因此,我们研究了这种治疗对TBI引发的SIRS的影响。在单次中度(2.5 - 3.0 atm)创伤性脑损伤后2小时,或在连续三次轻度(1.0 - 1.5 atm)液体冲击性TBI每次后的2小时和24小时给予抗CD11d治疗。假手术损伤、生理盐水处理的大鼠作为对照。在单次TBI后以及三次TBI中的第三次后的24小时、72小时和4或8周,对大鼠的肺进行组织化学、免疫细胞化学和生物化学检查,以检测SIRS的下游效应,包括炎症、组织损伤和氧化酶的表达。肺切片显示,单次中度和重复轻度TBI均导致肺泡破裂、肺泡间组织增厚、实质内出血以及肺泡内和肺泡周围巨噬细胞密度增加。抗CD11d治疗降低了这些TBI后肺内中性粒细胞的流入、活化巨噬细胞的密度以及髓过氧化物酶的活性。此外,蛋白质印迹研究表明,该治疗降低了肺中氧化酶gp91(phox)、诱导型一氧化氮合酶和环氧化酶-2的蛋白质水平,以及凋亡途径酶半胱天冬酶-3的水平和4-羟基壬烯醛结合蛋白的水平(脂质过氧化的指标)。细胞保护性转录因子Nrf2表达的降低反映了肺氧化应激的降低。抗CD11d治疗还降低了肺中自由基和组织醛的浓度。总之,通过一种简单、微创且持续时间短的抗炎治疗,可显著降低单次或重复TBI后SIRS中显著的肺部炎症反应。